Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 176

The DOI matches its Crossref record.

Initial Assessment of Tumor Regrowth After Vismodegib in Advanced Basal Cell Carcinoma

Open access
Chang, Anne Lynn S., Oro, Anthony E.·2012·Archives of Dermatology

Abstract

Secondary (acquired) resistance of a tumor to a chemotherapeutic agent is characterized by regrowth of a tumor after initial shrinkage.This is distinct from primary resistance, in which a tumor never responds to treatment, a separate topic from our current study.The Smoothened (SMO) inhibitor, vismodegib (GDC-0449), has recently been shown to be useful in phase 1 and 2 clinical trials 1-3 for locally advanced basal cell carcinomas (laBCCs) (defined as inoperable owing to multiple postsurgical recurrences or incurable with surgery without significant deformity or loss of function) or meta-static BCCs (mBCCs).Collectively, laBCCs and mBCCs are termed advanced BCCs, and vismodegib treatment was approved in 2012 by the US Food and Drug Administration for this indication.Our case series describes a previously unreported phenomenon of BCC tumor re-growth within or immediately adjacent to (within 1 cm) the prior tumor bed of a vismodegib-responsive tumor while the patient is still undergoing continuous vismodegib treatment.We call this phenomenon secondary (acquired) resistance.4 MethodsWe conducted a retrospective medical chart review, approved by the Stanford human subjects panel, examining the records of 28 consequent patients with laBCC or mBCC treated with continuous administration of vismodegib and observed from 4 to 162 weeks (until any-cause death or last clinic visit).All patients were seen at Stanford Hospital and Clinics on a monthly basis.All patients had been enrolled as part of 3 vismodegib clinical trials with identical inclusion and exclusion criteria (NCT00833417, NCT00959647, and NCT01160250), including at least 1 laBCC or mBCC, and had no treatment breaks during follow-up time.Twenty-one patients were men, and 7 were women. ResultsOf treated patients, 21% developed at least 1 tumor regrowth while undergoing continuous vismodegib treatment, with a mean (SD) time to detected re-growth by clinical examination of 56.4 (52.3) weeks (Table ).The BCCs with regrowth represented 8% of all BCCs (including laBCCs, mBCCs, and nonadvanced BCCs) observed during vismodegib

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/archdermatol.2012.2354

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 176

Metadata

Authors
Chang, A. L. S., & Oro, A. E.
Venue
Archives of Dermatology
Published
2012-11-01
Volume
148
Issue
11
Pages
1324
ISSN
0003-987X (ISSN-L)
OpenAlex
W1986357982
Cited by
176
References
0
FWCI
6.16
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Initial Assessment of Tumor Regrowth After Vismodegib in Advanced Basal Cell Carcinoma. https://app.cochat.ai/papers/10.1001/archdermatol.2012.2354
The paper
Chang, A. L. S., & Oro, A. E. (2012). Initial Assessment of Tumor Regrowth After Vismodegib in Advanced Basal Cell Carcinoma. Archives of Dermatology. https://doi.org/10.1001/archdermatol.2012.2354

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.